All Stories

  1. Further Characterization of the Antiviral Transmembrane Protein MARCH8

    Article • Cells, April 2024, MDPI AG

    Dr Kenzo Tokunaga

  2. Membrane-Associated Ubiquitin Ligase RING Finger Protein 152 Orchestrates Melanogenesis via Tyrosinase Ubiquitination

    Article • Membranes, February 2024, MDPI AG

    Dr Kenzo Tokunaga

  3. Membrane-Associated Ubiquitin Ligase RNF152 Orchestrates Melanogenesis via Tyrosinase Ubiquitination

    Article • December 2023, MDPI AG

    Dr Kenzo Tokunaga

  4. Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection

    Article • Proceedings of the National Academy of Sciences, December 2023, Proceedings of the National Academy of Sciences

    Tadaki Suzuki, Dr Kenzo Tokunaga

  5. Membrane-Associated Ubiquitin Ligase RNF152 Orchestrates Melanogenesis via Tyrosinase Ubiquitination

    Article • December 2023, MDPI AG

    Dr Kenzo Tokunaga

  6. Membrane-Associated Ubiquitin Ligase RNF152 Orchestrates Melanogenesis via Tyrosinase Ubiquitination

    Article • December 2023, MDPI AG

    Dr Kenzo Tokunaga

  7. Determination of the factors responsible for the tropism of SARS-CoV-2-related bat coronaviruses to Rhinolophus bat ACE2

    Article • Journal of Virology, September 2023, ASM Journals

    Dr Kenzo Tokunaga

  8. Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti–SARS-CoV-2 antibodies in the absence of CXCL13

    Article • Science Advances, August 2023, American Association for the Advancement of Science

    Dr Kenzo Tokunaga

  9. Construction and evaluation of a self-replicative RNA vaccine against SARS-CoV-2 using yellow fever virus replicon

    Article • PLoS ONE, October 2022, PLOS

    Dr Kenzo Tokunaga

  10. Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants

    Article • Med, April 2022, Elsevier

    Dr Kenzo Tokunaga

  11. MARCH8 Targets Cytoplasmic Lysine Residues of Various Viral Envelope Glycoproteins

    Article • Microbiology Spectrum, February 2022, ASM Journals

    Dr Kenzo Tokunaga

  12. Characterization of the Immune Resistance of Severe Acute Respiratory Syndrome Coronavirus 2 Mu Variant and the Robust Immunity Induced by Mu Infection

    Article • The Journal of Infectious Diseases, February 2022, Oxford University Press (OUP)

    Dr Kenzo Tokunaga

  13. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant

    Article • Nature, February 2022, Springer Science + Business Media

    Dr Kenzo Tokunaga

  14. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity

    Article • Nature, February 2022, Springer Science + Business Media

    Dr Kenzo Tokunaga, Dr Sarah E Jackson

  15. The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance

    Article • Cell Reports, January 2022, Elsevier

    Dr Kenzo Tokunaga

  16. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation

    Article • Nature, November 2021, Springer Science + Business Media

    Dr Kenzo Tokunaga

  17. SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion

    Article • The Journal of Infectious Diseases, September 2021, Oxford University Press (OUP)

    Dr Kenzo Tokunaga

  18. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

    Article • Nature, September 2021, Springer Science + Business Media

    Dr Kenzo Tokunaga, Professor RAJU VAISHYA, Dr Sarah E Jackson

  19. Aromatic Side Chain at Position 412 of SERINC5 Exerts Restriction Activity toward HIV-1 and Other Retroviruses

    Article • Journal of Virology, August 2021, ASM Journals

    Dr Kenzo Tokunaga

  20. Phenotypic and Genotypic Co-receptor Tropism Testing in HIV-1 Epidemic Region of Tanzania Where Multiple Non-B Subtypes Co-circulate

    Article • Frontiers in Microbiology, July 2021, Frontiers

    Dr Kenzo Tokunaga

  21. MARCH8: the tie that binds to viruses

    Article • FEBS Journal, May 2021, Wiley

    Dr Kenzo Tokunaga

  22. MARCH8 targets cytoplasmic lysine residues of various viral envelope glycoproteins

    Article • April 2021, Cold Spring Harbor Laboratory Press

    Dr Kenzo Tokunaga

  23. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity

    Article • Nature Communications, February 2021, Springer Science + Business Media

    Dr Kenzo Tokunaga

  24. MARCH8 inhibits viral infection by two different mechanisms

    Article • eLife, August 2020, eLife

    Dr Kenzo Tokunaga

  25. Super-rapid quantitation of the production of HIV-1 harboring a luminescent peptide tag

    Article • Journal of Biological Chemistry, July 2020, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Kenzo Tokunaga

  26. Naturally mutated spike proteins of SARS-CoV-2 variants show differential levels of cell entry

    Article • June 2020, Cold Spring Harbor Laboratory Press

    Dr Kenzo Tokunaga

  27. Super-rapid quantitation of the production of HIV-1 harboring a luminescent peptide tag

    Article • April 2020, Cold Spring Harbor Laboratory Press

    Dr Kenzo Tokunaga

  28. MARCH8 inhibits viral infection by two different mechanisms

    Article • April 2020, Cold Spring Harbor Laboratory Press

    Dr Kenzo Tokunaga

  29. CRISPR-mediated activation of endogenous BST-2/tetherin expression inhibits wild-type HIV-1 production

    Article • Scientific Reports, February 2019, Springer Science + Business Media

    Dr Kenzo Tokunaga

  30. Membrane-associated RING-CH (MARCH) 1 and 2 are MARCH family members that inhibit HIV-1 infection

    Article • Journal of Biological Chemistry, January 2019, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Kenzo Tokunaga

  31. Homeostatically Maintained Resting Naive CD4+ T Cells Resist Latent HIV Reactivation

    Article • Frontiers in Microbiology, December 2016, Frontiers

    Dr Kenzo Tokunaga

  32. Critical Contribution of Tyr15 in the HIV-1 Integrase (IN) in Facilitating IN Assembly and Nonenzymatic Function through the IN Precursor Form with Reverse Transcriptase

    Article • Journal of Virology, October 2016, ASM Journals

    Dr. Takao Masuda, Dr Kenzo Tokunaga

  33. An HIV-1 capsid binding protein TRIM11 accelerates viral uncoating

    Article • Retrovirology, October 2016, Springer Science + Business Media

    Dr Kenzo Tokunaga

  34. MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins

    Article • Nature Medicine, November 2015, Springer Science + Business Media

    Dr Kenzo Tokunaga

  35. Anti-APOBEC3G Activity of HIV-1 Vif Protein Is Attenuated in Elite Controllers

    Article • Journal of Virology, February 2015, ASM Journals

    Dr Kenzo Tokunaga

  36. The HIV-1 accessory protein Vpr induces the degradation of the anti-HIV-1 agent APOBEC3G through a VprBP-mediated proteasomal pathway

    Article • Virus Research, January 2015, Elsevier

    Dr Kenzo Tokunaga

  37. Identification of an antiviral host transmembrane protein MARCH8

    Article • Uirusu, January 2015, Japanese Association of Virology

    Dr Kenzo Tokunaga

  38. Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site

    Article • Retrovirology, January 2014, Springer Science + Business Media

    Dr Kenzo Tokunaga

  39. APOBEC3G Oligomerization Is Associated with the Inhibition of Both Alu and LINE-1 Retrotransposition

    Article • PLoS ONE, December 2013, PLOS

    Dr Kenzo Tokunaga

  40. Membrane-associated RING-CH (MARCH) 8 mediates the ubiquitination and lysosomal degradation of the transferrin receptor

    Article • Journal of Cell Science, April 2013, The Company of Biologists

    Dr Kenzo Tokunaga

  41. Characteristics of IFITM, the newly identified IFN-inducible anti-HIV-1 family proteins

    Article • Microbes and Infection, April 2013, Elsevier

    Dr Kenzo Tokunaga

  42. DNA damage enhances integration of HIV-1 into macrophages by overcoming integrase inhibition

    Article • Retrovirology, January 2013, Springer Science + Business Media

    Dr Kenzo Tokunaga

  43. Transgenic expression of the human LEDGF/p75 gene relieves the species barrier against HIV-1 infection in mouse cells

    Article • Frontiers in Microbiology, January 2013, Frontiers

    Dr Kenzo Tokunaga

  44. Host restriction factors in retroviral infection: promises in virus-host interaction

    Article • Retrovirology, December 2012, Springer Science + Business Media

    Dr Kenzo Tokunaga

  45. Susceptibility of HIV-1 CRF01_AE viruses to a CD4-binding site monoclonal antibody, IgG1 b12

    Article • International Journal of Infectious Diseases, June 2012, Elsevier

    Dr Kenzo Tokunaga

  46. Editorial: HIV-1 Vpu and BST-2/Tetherin: Enemies at the Gates

    Article • Current HIV Research, May 2012, Bentham Science Publishers

    Dr Kenzo Tokunaga

  47. Sites of Action of HIV-1 Vpu in BST-2/Tetherin Downregulation

    Article • Current HIV Research, May 2012, Bentham Science Publishers

    Dr Kenzo Tokunaga

  48. Intracellular Logistics of BST-2/Tetherin

    Article • Current HIV Research, May 2012, Bentham Science Publishers

    Dr Kenzo Tokunaga

  49. Retroelements versus APOBEC3 family members: No great escape from the magnificent seven

    Article • Frontiers in Microbiology, January 2012, Frontiers

    Dr Kenzo Tokunaga

  50. Epigenetic displacement of HP1 from heterochromatin by HIV-1 Vpr causes premature sister chromatid separation

    Article • The Journal of Cell Biology, August 2011, Rockefeller University Press

    Dr Kenzo Tokunaga

  51. Identification of SNF2h, a Chromatin-Remodeling Factor, as a Novel Binding Protein of Vpr of Human Immunodeficiency Virus Type 1

    Article • Journal of Neuroimmune Pharmacology, April 2011, Springer Science + Business Media

    Dr Kenzo Tokunaga

  52. Intrinsic restriction activity by apolipoprotein B mRNA editing enzyme APOBEC1 against the mobility of autonomous retrotransposons

    Article • Nucleic Acids Research, March 2011, Oxford University Press (OUP)

    Dr Kenzo Tokunaga

  53. Homodimerization of APOBEC3G is required for inhibition of Alu retrotransposition

    Article • Retrovirology, January 2011, Springer Science + Business Media

    Dr Kenzo Tokunaga

  54. Structural Basis for the Antiviral Activity of BST-2/Tetherin and Its Viral Antagonism

    Article • Frontiers in Microbiology, January 2011, Frontiers

    Dr Kenzo Tokunaga

  55. Differential Anti-APOBEC3G Activity of HIV-1 Vif Proteins Derived from Different Subtypes

    Article • Journal of Biological Chemistry, September 2010, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Kenzo Tokunaga

  56. The role of lysine residue at amino acid position 165 of human immunodeficiency virus type 1 CRF01_AE Gag in reducing viral drug susceptibility to protease inhibitors

    Article • Virology, September 2010, Elsevier

    Dr Kenzo Tokunaga

  57. Direct internalization of cell-surface BST-2/tetherin by the HIV-1 accessory protein Vpu

    Article • Communicative & Integrative Biology, July 2010, Taylor & Francis

    Dr Kenzo Tokunaga

  58. Combined analysis of cell growth and apoptosis-regulating proteins in HPVs associated anogenital tumors

    Article • BMC Cancer, March 2010, Springer Science + Business Media

    Dr Kenzo Tokunaga

  59. Two N-Linked Glycosylation Sites in the V2 and C2 Regions of Human Immunodeficiency Virus Type 1 CRF01_AE Envelope Glycoprotein gp120 Regulate Viral Neutralization Susceptibility to the Human Monoclonal Antibody Specific for the CD4 Binding Domain

    Article • Journal of Virology, February 2010, ASM Journals

    Dr Kenzo Tokunaga

  60. Impact of Amino Acid Variations in Gag and Protease of HIV Type 1 CRF01_AE Strains on Drug Susceptibility of Virus to Protease Inhibitors

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, November 2009, Wolters Kluwer Health

    Dr Kenzo Tokunaga

  61. HIV-1 Accessory Protein Vpu Internalizes Cell-surface BST-2/Tetherin through Transmembrane Interactions Leading to Lysosomes

    Article • Journal of Biological Chemistry, October 2009, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Kenzo Tokunaga

  62. Evaluation of telomerase activity in non-genital Bowen's disease

    Article • Journal of the European Academy of Dermatology and Venereology, June 2009, Wiley

    Dr Kenzo Tokunaga

  63. Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01_AE env gene derived from HIV-1-infected patient, residing in central Thailand

    Article • Microbes and Infection, March 2009, Elsevier

    Dr Kenzo Tokunaga

  64. Genotypic Characterization of CRF01_AE env Genes Derived from Human Immunodeficiency Virus Type 1-Infected Patients Residing in Central Thailand

    Article • AIDS Research and Human Retroviruses, February 2009, Mary Ann Liebert Inc

    Dr Kenzo Tokunaga

  65. Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry

    Article • Proceedings of the National Academy of Sciences, June 2008, Proceedings of the National Academy of Sciences

    Dr Kenzo Tokunaga

  66. Inhibitory function of adapter-related protein complex 2 alpha 1 subunit in the process of nuclear translocation of human immunodeficiency virus type 1 genome

    Article • Virology, March 2008, Elsevier

    Dr Kenzo Tokunaga

  67. Identification of the suppressive factors for human immunodeficiency virus type-1 replication using the siRNA mini-library directed against host cellular genes

    Article • Biochemical and Biophysical Research Communications, August 2007, Elsevier

    Dr Kenzo Tokunaga

  68. All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition

    Article • Nucleic Acids Research, April 2007, Oxford University Press (OUP)

    Dr Kenzo Tokunaga

  69. Successful Mouse Cloning of an Outbred Strain by Trichostatin A Treatment after Somatic Nuclear Transfer

    Article • Journal of Reproduction and Development, January 2007, Japanese Society of Animal Reproduction

    Dr Kenzo Tokunaga

  70. HIV-1 Vpr induces ATM-dependent cellular signal with enhanced homologous recombination

    Article • Oncogene, September 2006, Springer Science + Business Media

    Dr Kenzo Tokunaga

  71. Tristetraprolin inhibits HIV-1 production by binding to genomic RNA

    Article • Microbes and Infection, September 2006, Elsevier

    Dr Kenzo Tokunaga

  72. HIV-1 Vpr Induces DNA Double-Strand Breaks

    Article • Cancer Research, January 2006, American Association for Cancer Research (AACR)

    Dr Kenzo Tokunaga

  73. Premature sister chromatid separation in HIV-1-infected peripheral blood lymphocytes

    Article • AIDS, September 2005, Wolters Kluwer Health

    Dr Kenzo Tokunaga

  74. HIV‐1 Proteases from Drug‐Naive West African Patients Are Differentially Less Susceptible to Protease Inhibitors

    Article • Clinical Infectious Diseases, July 2005, Oxford University Press (OUP)

    Dr Kenzo Tokunaga

  75. Amino Acid 36 in the Human Immunodeficiency Virus Type 1 gp41 Ectodomain Controls Fusogenic Activity: Implications for the Molecular Mechanism of Viral Escape from a Fusion Inhibitor

    Article • Journal of Virology, May 2005, ASM Journals

    Dr Kenzo Tokunaga

  76. Interleukin-4 Up-Regulates T-Tropic Human Immunodeficiency Virus Type 1 Transcription in Primary CD4+CD38+T-Lymphocyte Subset

    Article • Microbiology and Immunology, February 2005, Wiley

    Dr Kenzo Tokunaga

  77. Human APOBEC3F Is Another Host Factor That Blocks Human Immunodeficiency Virus Type 1 Replication

    Article • Journal of Virology, June 2004, ASM Journals

    Dr Kenzo Tokunaga

  78. Nucleolin and the Packaging Signal, ψ, Promote the Budding of Human Immunodeficiency Virus Type-1 (HIV-1)

    Article • Microbiology and Immunology, February 2004, Wiley

    Dr Kenzo Tokunaga

  79. Human topoisomerase I promotes HIV-1 proviral DNA synthesis: Implications for the species specificity and cellular tropism of HIV-1 infection

    Article • Proceedings of the National Academy of Sciences, June 2003, Proceedings of the National Academy of Sciences

    Dr Kenzo Tokunaga

  80. Interleukin-8-mediated Heterologous Receptor Internalization Provides Resistance to HIV-1 Infectivity

    Article • Journal of Biological Chemistry, February 2003, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Kenzo Tokunaga

  81. Requirement of Nef for HIV-1 infectivity is biased by the expression levels of Env in the virus-producing cells and CD4 in the target cells

    Article • Archives of Virology, September 2001, Springer Science + Business Media

    Dr Kenzo Tokunaga

  82. Molecular Basis for Cell Tropism of CXCR4-Dependent Human Immunodeficiency Virus Type 1 Isolates

    Article • Journal of Virology, August 2001, ASM Journals

    Dr Kenzo Tokunaga

  83. The Cellular Kinase Binding Motifs (PxxP and RR) in Human Immunodeficiency Virus Type 1 Nef Protein Are Dispensable for Producer-Cell-Dependent Enhancement of Viral Entry

    Article • Virology, May 1999, Elsevier

    Dr Kenzo Tokunaga

  84. Enhancement of human immunodeficiency virus type 1 infectivity by Nef is producer cell-dependent.

    Article • Journal of General Virology, October 1998, Society for General Microbiology

    Dr Kenzo Tokunaga

  85. Producer Cell-Dependent Requirement of the Nef Protein for Efficient Entry of HIV-1 into Cells

    Article • Biochemical and Biophysical Research Communications, September 1998, Elsevier

    Dr Kenzo Tokunaga

  86. Vulnerability to arrhythmias during social stress in rats with different sympathovagal balance

    Article • AJP Heart and Circulatory Physiology, August 1998, American Physiological Society

    Dr Kenzo Tokunaga

  87. Inhibition of Human Immunodeficiency Virus Type 1 Virion Entry by Dominant-Negative Hck

    Article • Journal of Virology, July 1998, ASM Journals

    Dr Kenzo Tokunaga

  88. Growth ability of auxiliary gene mutants of human immunodeficiency virus types 1 and 2 in unstimulated peripheral blood mononuclear cells

    Article • Archives of Virology, January 1997, Springer Science + Business Media

    Dr Kenzo Tokunaga

  89. Naturally occurring accessory gene mutations lead to persistent human immunodeficiency virus type 1 infection of CD4-positive T cells

    Article • Journal of Virology, December 1995, ASM Journals

    Dr Kenzo Tokunaga

  90. Function of human immunodeficiency virus type 1 Vpu protein in various cell types

    Article • Journal of General Virology, November 1995, Society for General Microbiology

    Dr Kenzo Tokunaga

  91. Early replication block of human immunodeficiency virus type 1 in monkey cells

    Article • Journal of General Virology, November 1995, Society for General Microbiology

    Dr Kenzo Tokunaga

  92. Generation and Characterization of a Host Cell-Dependent gag Gene Mutant of Human Immunodeficiency Virus Type 1

    Article • Virology, September 1995, Elsevier

    Dr Kenzo Tokunaga

  93. Rev-dependency of expression of human immunodeficiency virus type 1 gag and env genes

    Article • FEBS Letters, May 1995, Wiley

    Dr Kenzo Tokunaga

  94. Functional analysis of human spuma retrovirus genome

    Article • Virus Genes, February 1995, Springer Science + Business Media

    Dr Kenzo Tokunaga

  95. Functionality of chimeric Rev proteins of HIV/SIV

    Article • Virus Genes, February 1995, Springer Science + Business Media

    Dr Kenzo Tokunaga

  96. Maintenance of high virus load even after seroconversion in newborn cats acutely infected with feline immunodeficiency virus

    Article • Vaccine, January 1995, Elsevier

    Dr Kenzo Tokunaga

  97. Superinfection of a Defective Human Immunodeficiency Virus Type 1 Provirus-Carrying T Cell Clone with vif or vpu Mutants Gives Cytopathic Virus Particles by Homologous Recombination

    Article • AIDS Research and Human Retroviruses, January 1995, Mary Ann Liebert Inc

    Dr Kenzo Tokunaga

  98. Increased anti-HIV-1 activity of CD4 CDR3-related synthetic peptides by scrambling and further structural modifications, including d -isomerization and dimerization

    Article • FEBS Letters, September 1993, Wiley

    Dr Kenzo Tokunaga

  99. Expression of human immunodeficiency virus type 1 Nef antigen on the surface of acutely and persistently infected human T cells

    Article • Vaccine, January 1993, Elsevier

    Dr Kenzo Tokunaga

  100. Altered cell tropism and cytopathicity of feline immunodeficiency viruses in two different feline CD4-positive, CD8-negative cell lines

    Article • Journal of Virology, June 1992, ASM Journals

    Dr Kenzo Tokunaga